Danburstotug
As of the edition of 20 October 2026, Danburstotug is an antibody: in active development; acts on CD274.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 8, 3 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Heart and blood vessels; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Danburstotug.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 1 | 1 |
| Phase 2 | 5 | 0 | 3 | 2 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| ImmuneOncia Therapeutics | Lead sponsor of trials | 2018 to now |
| Sorrento Therapeutics | Lead sponsor of trials | 2021 to now |
| ImmuneOnco Biopharmaceuticals | Lead sponsor of trials | 2025 to now |